Although various mutations are associated with upregulation of PD-L1 expression in tumor cells, the mechanisms of decreased efficacy of ICI on EGFR-and ALK-driven NSCLC remains unclear (13, 14). This evidence concerns the gene ALK and non-small cell lung carcinoma.